At the time of diagnosis, approximately 60%-80% of patients with hypopharyngeal cancer are found with cervical lymph node metastasis. Cervical nodal metastasis is an important prognostic factor in hypopharyngeal cancer. Induction chemotherapy is frequently used in advanced hypopharynx cancer. However, sometimes CR was obtained at the tumor's primary site but not in the palpable lymph nodes in the neck, the large cervical lymph node metastasis poorly responded to induction chemotherapy in a considerable percentage of patients. At present, patients with primary tumor achieved CR preferred to receive definitive radiotherapy no matter cervical lymph node metastasis SD or progression. But, radiotherapy was poor effective to the big cervical lymph node metastasis, because the inner of big cervical lymph node metastasis was hypoxic and necrosis. The investigators conducted a prospective, randomised trial to compare neck dissection with definitive radiotherapy for advanced hypopharyngeal cancer cervical lymph node metastasis with poor response to induction chemotherapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Neck dissection followed by radiotherapy(50Gy) according to risk factors
Definitive radiotherapy (70Gy)
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Neck control rates
The percentage of patients without cervical lymph node metastasis
Time frame: 2 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 1 year
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 2 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 3 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 5 years
Overall survival
The proportion of patients who survived
Time frame: 3 years
Overall survival
The proportion of patients who survived
Time frame: 5 years
Quality of life(QOL) QLQ-C30
Evaluated by the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30
Time frame: 1 year
Quality of life(QOL) QLQ-HN35
Evaluated by the European Organization for Research and Treatment of Cancer(EORTC) QLQ-HN35
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.